TMO Q1 2026 Earnings Analysis

Welcome to Beta Finch, your AI-powered earnings breakdown where we decode the numbers that matter. I'm Alex.

Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

Well, the headline numbers are decent but not spectacular. Revenue grew 6% to $11.01 billion, and adjusted EPS came in at $5.44, also up 6%. But here's the kicker - they actually beat their own guidance by 14 cents per share on the earnings side.

Exactly. And on earnings, they're now expecting $24.64 to $25.12 per share, up from their original $24.22 to $24.80 guide. That represents 8% to 10% growth for the year. But Jordan, there's a big asterisk here - a lot of this guidance raise comes from their massive Clario acquisition.

And CEO Marc Casper was pretty excited about it on the call. He kept talking about how it enhances their "trusted partner status" with pharma and biotech customers. The integration seems to be going smoothly, and customers are apparently enthusiastic about combining Thermo's capabilities with Clario's digital endpoints technology.

Yeah, this is where it gets interesting. They had some real operational challenges. First, they had one less selling day compared to last year, which dinged organic growth by about a percentage point. Then there was revenue phasing in pharma services - another roughly one-point headwind.

Casper seemed pretty confident though. He said the markets are playing out exactly as expected, and the ramp isn't really assuming any change in underlying market conditions. It's more about these timing issues and comparisons normalizing.

Meanwhile, Analytical Instruments was flat on revenue with organic declining 2%. This is the ongoing story we've been hearing across the industry - weak academic and government spending, especially in the US and China. Margins in that segment got hit hard, down 250 basis points to 20.7%.

The China situation is worth highlighting too. China is about 7.5% of their revenue, and it declined low single digits in the quarter. But here's what's interesting - Casper visited China in March and came back "incrementally more positive." He's seeing Chinese pharma and biotech innovators recognizing the value of working with Thermo Fisher to compete globally.

Which theoretically means more funding for biotech and more business for Thermo Fisher down the line. He's planning to elaborate on this at their Analyst Day on May 20th, 2026.

But they maintained their $3 billion share buyback assumption for the year - actually, they completed that all in January. They also raised their dividend 10%. So they're still returning capital to shareholders while making this big strategic bet on Clario.

That's prudent given the macro uncertainty. But Casper emphasized their PPI Business System - their operational excellence program - gives them confidence they can offset inflationary pressures through productivity improvements.

I think that's fair. The pharma and biotech exposure is clearly the growth engine right now, and the Clario acquisition doubles down on that bet. But the academic and government weakness, particularly in instruments, is a real drag that doesn't seem to be improving meaningfully.

Looking ahead, the key will be whether they can execute on this acceleration they need in the back half of the year. The comparisons get easier, and they have some seasonal tailwinds, but it's always risky to rely on a big fourth quarter.

Any final thoughts on valuation or positioning?

Agreed. It's a quality name with good long-term prospects, but probably not a screaming buy at current levels unless you're really bullish on the pharma innovation cycle.

Thanks for tuning into Beta Finch. We'll be back next time with another AI-powered earnings breakdown. Until then, keep those portfolios diversified and those expectations realistic.